Variable | SLE patients (n = 11) | Matched controls (n = 11) | p value†|
---|---|---|---|
Demographics | |||
 Age, years* | 19.5 ± 4.2 | 17.0 ± 6.8 | 0.312 |
 Females (n) | 10 | 10 | 1.000 |
 Race (African American, n)@ | 6 | 6 | 1.000 |
 Income (n < $50,000/year)** | 6 | 8 | 0.658 |
 Median family income ($)* (US census based on ZIP) | 64,090.91 ± 41,690.42 | 59,857.09 ± 9700.90 | 0.746 |
Physical exam findings | |||
 Body mass index (BMI)* | 23.0 ± 4.9 | 25.9 ± 4.1 | 0.148 |
 Blood pressure (mmHg) | |||
  Systolic* | 115.4 ± 15.4 | 120.6 ± 10.9 | 0.372 |
  Diastolic* | 72.2 ± 7.3 | 69.4 ± 5.3 | 0.316 |
Neurocognitive assessment# | |||
 Domains (Z-score)* | |||
  (1)Working memory | 0.06 ± 0.72 | − 0.34 ± 0.65 | 0.187 |
  (2)Psychomotor speed | 0.15 ± 0.88 | − 0.15 ± 0.55 | 0.349 |
  (3)Attention | 0.34 ± 0.77 | − 0.07 ± 0.90 | 0.264 |
  (4)Visuoconstructional ability | 0.46 ± 0.45 | − 0.15 ± 0.56 | 0.610 |
SLE measures‡ | |||
 Disease duration, years* | 6.3 ± 4.3 | – |  |
 ds DNA positive (n) | 5 | – |  |
 Complement C3* (mg/dl) | 96.9 ± 29.3 | – |  |
 Complement C4* (mg/dl) | 17.4 ± 8.9 | – |  |
 SLEDAI* | 5.7 ± 4.7 | – |  |
 SLICC-ACR damage index (median (range)) | 0 (0–4) | – |  |
Prednisone use (n) | |||
 None | 2 | – |  |
 ≤ 5 mg/day | 7 | – |  |
 > 5 mg/day | 2 | – |  |